Silexion Therapeutics Corp
SLXNW- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0002022416
No open-market purchases or sales by Silexion Therapeutics Corp insiders were filed in the last 90 days; 19 institutions reported holding it in 13F filings for Q2 2026, worth $98.7K in total; no superinvestor holds it.
Other share classesSLXN
13F holders, Q2 2026
Institutional positions in Silexion Therapeutics Corp as of Jun 30, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 19
- 0 vs. Q1 2026
- Shares held
- 2.42M
- +81.1K (+3.5%) vs. Q1 2026
- Total value
- $98.7K
- +$36.7K (+59.2%) vs. Q1 2026
- New holders
- 1
- 1 more added
- Sold out
- 1
- 1 more reduced
Compare with Q1 2026: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting SLXNW on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 19 | $98.7K |
| Q1 2026 | 19 | $62.0K |
| Q4 2025 | 22 | $83.1K |
| Q3 2025 | 22 | $127.5K |
| Q2 2025 | 22 | $107.6K |
| Q1 2025 | 25 | $199.1K |
| Q4 2024 | 26 | $91.7K |
| Q3 2024 | 32 | $106.1K |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2026
Shares, value and share of portfolio for each institution holding Silexion Therapeutics Corp; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Oasis Management Co Ltd. | 11,111 | $28.3K | 0.00% | 00.0% | Unchanged |
| Polar Asset Management Partners Inc. | 743,475 | $20.8K | 0.00% | 00.0% | Unchanged |
| Linden Advisors LP | 337,500 | $9.48K | 0.00% | 00.0% | Unchanged |
| Aristeia Capital LLC | 236,546 | $6.63K | 0.00% | 00.0% | Unchanged |
| Clear Street Group Inc. | 218,165 | $6.63K | 0.00% | −600−0.3% | Reduced |
| Security Benefit Life Insurance Co | 150,000 | $4.56K | 0.00% | 00.0% | Unchanged |
| Goldman Sachs Group Inc | 125,103 | $3.80K | 0.00% | +1,609+1.3% | Added |
| Kepos Capital LP | 100,000 | $3.00K | 0.00% | 00.0% | Unchanged |
| Susquehanna International Group, LLP | 92,073 | $2.80K | 0.00% | +92,073 | New |
| Jane Street Group, LLC | 74,910 | $2.28K | 0.00% | 00.0% | Unchanged |
| Picton Mahoney Asset Management | 57,175 | $1.74K | 0.00% | 00.0% | Unchanged |
| Context Capital Management, LLC | 51,183 | $1.56K | 0.00% | 00.0% | Unchanged |
| Tenor Capital Management Co., L.P. | 50,000 | $1.52K | 0.00% | 00.0% | Unchanged |
| Gabelli & Co Investment Advisers, Inc. | 38,150 | $1.16K | 0.00% | 00.0% | Unchanged |
| Mint Tower Capital Management B.V. | 25,000 | $1.00K | 0.00% | 00.0% | Unchanged |
| DuPont Capital Management Corp | 32,500 | $988 | 0.05% | 00.0% | Unchanged |
| Neuberger Berman Group LLC | 31,552 | $959 | 0.00% | 00.0% | Unchanged |
| Gabelli Funds LLC | 30,496 | $927 | 0.00% | 00.0% | Unchanged |
| Stifel Financial Corp | 16,000 | $486 | 0.00% | 00.0% | Unchanged |
| Saba Capital Management, L.P. | 0 | $0 | 0.00% | −11,937−100.0% | Sold out |